[Form 4] Sarepta Therapeutics,, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider award: On 08/05/2025 Sarepta Therapeutics (SRPT) President of R&D and Tech Ops, Louise Rodino-Klapac, earned 6,250 Performance Stock Units (PSUs) according to a Form 4 filing. The PSUs stem from a grant dated 03/01/2024 and were unlocked after the Compensation Committee confirmed the company met specific milestones. No cash was paid (exercise price $0) and there were no share sales or disposals. All 6,250 PSUs remain un-vested and are scheduled to vest on 03/01/2026, contingent on continued employment. Following the transaction the executive beneficially owns 6,250 derivative securities directly. The filing signals milestone achievement but represents a small ownership change relative to Sarepta’s total share count, implying limited dilution or immediate market impact.

Positive

• Milestone achievement: Company met preset goals, triggering issuance of 6,250 PSUs to the President of R&D and Tech Ops.

Negative

• None.

Insights

Equity Research Analyst

TL;DR: 6,250 PSUs earned; confirms milestone progress, financially immaterial.

The award shows Sarepta hit internal milestones tied to the March 2024 PSU grant, a qualitative positive for R&D execution. However, the share count is de-minimis versus SRPT’s ~85 million shares outstanding, so dilution and valuation impact are negligible. Because the units vest in 2026 and required no insider purchase, the transaction does not signal insider buying pressure. Overall, the filing is more an operational checkpoint than a market-moving event.

Corporate Governance Specialist

TL;DR: Routine incentive payout; aligns pay with performance.

Issuing PSUs upon milestone attainment supports a performance-linked compensation structure. Vesting deferral to 2026 keeps retention pressure on a key executive overseeing R&D. The size—6,250 shares—suggests conservative equity usage, limiting shareholder dilution. No red flags on disclosure or Rule 10b5-1 compliance appear. Governance impact is neutral to slightly positive.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodino-Klapac Louise

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D and Tech Ops

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	08/05/2025		A		6,250		(1)	(1)	Common Stock	6,250	$0	6,250	D

Explanation of Responses:

1. Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

	/s/ Cristin Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac	08/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for SRPT on 08/05/2025?

Louise Rodino-Klapac earned 6,250 Performance Stock Units based on milestone achievement; no shares were sold.

When will the newly earned PSUs for Sarepta’s executive vest?

The 6,250 PSUs are scheduled to vest on 03/01/2026, subject to continued service.

Did the insider pay anything to acquire the Sarepta PSUs?

No. The exercise price is $0; the units were earned through performance, not purchased on the market.

How many Sarepta shares does the executive now beneficially own after the filing?

Following the grant, the executive directly owns 6,250 derivative securities (PSUs).

Does this Form 4 indicate insider buying or selling of SRPT stock?

Neither. It reports a performance-based equity grant; there were no open-market purchases or sales.